About Us
The SMU Institute for Genetic Engineering Research (IGER), with biochemistry and molecular biology as its disciplinary basis and directly affiliated with the Southern Medical University (SMU), is an arm of the PLA Key Biochip Lab (one of the top 20 labs of the Army), Guangdong Provincial Key Biochip Lab and South China Biochip Research Center. The IGER is made up of six branches: the Teaching and Research Center for Biochemistry and Molecular Biology, the Experimental Teaching Center for Biochemistry and Molecular Biology, the Biochip Research Office, the Proteomics Research Office, the Genomics Research Office and the Bio-informatics Center. Taking the gene expression profile chip, protein chip and clinically-applied chip as its major fields, the IGER has the cutting edge in the domestic biochip field.
The IGER, the first of its kind in China, was established by Prof. Ma Wenli, head of the Institute, when she received the first funding by Chinese National Natural Science Foundation in 1998 after returning from a study at the National Institute of Health of the U.S.A. The IGER has made ground-breaking achievements in the three key biochip technologies, forged a platform for new and high technology in biochip with dependent intellectual property, which has been applied in regulating the health of the general public. In 2000, Prof. Ma advocated, for the first time, applying the biochip technology in the gene detecting for diseases and sub-health, specifically, in early diagnosis of diseases and in micro-regulation of life in sub-health. In 2004, Prof. Ma made the proposal for individualized health management in China by building human genetic files, a way which will enable the molecular-level CT, prevent the pathogenesis and development of malignant tumors, improve people’s health and increase their life span.
Covering an area of 3,900 square meters, the up-to-date lab is equipped with a whole set of modern molecular biological equipment, comprising OmnGrid 300 biochip deposition system, Agilent 2565B Scanner, ABI 3730 DNA sequence analyzer, ABI 3900 DNA synthesizer, Biomek2000 automated workstation, ABI7500 fluorescence ration PCR instrument, GE protein two-dimensional electrophoresis system, Infinite M200 Multi-purpose Enzyme Mark Instrument and Beckman High-speed Freezing Centrifuge, a ￥18 million’s worth of asset in total.
In recent years, the IGER has undertaken 16 national, provincial, municipal and military key break-through research programs, with a total fund of over ￥20 million. Additionally, the IGER has got over 290 medical research papers (49 SCI ones) published, among which one by a doctoral candidate (jointly educated by SMU and the Harvard Medical School) was published in the internationally notable journal CELL with SMU as the second authorship and was featured by Science and Nature. The IGER has authored 10 treatises and obtained 8 national patents for inventions and 3 for utility models. Moreover, the IGER has received various honorable titles at the state, provincial and military levels. Furthermore, as the designer of National Excellence Course of Biochemistry and Molecular Biology and the National Exemplary Course, the IGER has, in its role as the National Teaching Team and Guangdong Provincial Model Teaching Center, graduated 100-odd masters, doctors and post-doctor fellows, among whom 40 have been granted provincial and state scholarships and 6 have grown into doctorate tutors and disciplinary forerunners.
The IGER is staffed with nearly 100 research members. Of the 26 tenure researchers, there are 2 professors, 2 doctorate tutors and 4 master’s supervisors. The age of the staff members averages out at 35.
The IGER, while vigorously developing the human whole-genome detecting chip, the genetic detecting chip for human easily-contracted diseases, the drug resistance detecting chip and the microorganisms detecting chip, lays great emphasis on utilization of its research results, embarking on a road of industry-university-research integration and a vicious cycle of the disciplinary development.
The Lab ranks as a top biochip research center in South China. Taking biochips as the core of its development and the new and high tech platform with the independent intellectual property as the basis, and dedicated to innovation, IGER is capable of undertaking key life science research programs and colossal genetic detecting. The Lab is willing to share resources and make cooperation in all sincerity for the sake of unveiling the mysteries of life and improving the quality of life, making its contributions to revitalizing China through science and education.
Research Area
This Lab focuses on the biochip detecting technology, bio-informatics analysis of high-throughput data and the molecular mechanism behind the pathogenesis of tumors.
1. Research in the application of biochip detecting technology
This Lab, by optimizing the design of the biochip probe, the platform for the biochip production technique and quality control and the platform for detecting technique, and by formulating standards of diagnosis, has applied the self-designed oligonucleotide detecting chip system in the high-throughput detection of multi-pathogeny. This Lab has also developed the EV71 detection biochip, the four-blood-pathogene (HIV, HBV, HCV and Syphilis ) integrated detection biochip and genetically-modified food detection biochip.
2. Bio-informatics analysis of high-throughput data
The advances in the bio-technology and the increasingly intense research into life have entailed an ocean of data. This Lab conducts the meta-analysis of the data with the bio-informatics method. It studies specific genes, screens biological targets and drugs, and explores the mutual regulation and dependence between genes for building a complete network for genetic control and regulation. In terms of analysis of bio-data, this Lab exerts itself to forge a platform for meta-analysis of bio-data with features for in-depth digging-up.
3. Molecular mechanism of the pathogenesis of tumors
This Lab, by utilizing the gene chip technology, fluorescence quantitative PCR and proteomics technology, probes the pathogenesis and progression of malignant tumors (liver cancer, breast cancer, etc.) and thus screens out significant tumor genes and tumor suppressor genes such as FBXO31, Pin1, PinX1, FKB38 and AQP1. Then the Lab studies proteins and DNAs which mutually acts with the genes sorted out for defining the network of mutual action and the signaling pathway and disclosing the related molecular mechanism. This will unveil the molecular mechanism underlying the pathogenesis and progression of tumors and providing new targets and a fresh line of thought for tumor treatment.
Research Features
1. Breakthroughs have been made in talents cultivation and echelon building.
2. With the introduction of new and high tech into teaching, outstanding achievements have been made.
Bringing into full play the advantages in scientific research, this Lab has introduced related scientific research results by the faculty into teaching by transforming the researches into students’ genetic biochip innovation experiments. With the scientific research facilities accessible to the undergraduates, this Lab is a base for innovation teaching with the SMU, which is composed of six research groups: Biochip, Genetic Diagnosis, Genetic Sequencing, Genetic Synthesis, Proteomics and Bioinformatics.
3. The industrialization of scientific research results has taken shape in its embryonic form.
This lab, which boasts 11 patents for national invention patents and 3 for utility new models, attaches importance to the industrialization of scientific research results. For this end, this Lab has taken various measures, including: increasing the cooperation with hospitals, emphasizing inclusion of industry-related content in the research, cracking clinical hard nuts related to clinical basis; developing diagnostic reagents and increasing the clinical access of the biochip tech; making cooperation with bio-tech companies in developing related products based on the needs of the market. All these efforts have entailed the fusion of scientific research and the industry, winning a total of funds of ￥ over 800 thousand for its vertical research programs and laying a solid foundation for industry-university-research cooperation, industrialization of research results and talents developing in the future.
Research Team
l Professor Ma Wenli, Director of the key Lab, doctorate tutor, is now Director of SMU Genetic Engineering Research Institute, Director of South China Center for Bio-chip Research, Director of Guangdong Provincial Key Lab for Biochips, Vice-chairman of Guangdong Provincial Bio-chemistry and Molecular Biology Association, Permanent Executive Member of Guangdong Provincial Society for Foreign Exchanges, Executive Member of the Chinese Bio-chemistry and Molecular Biology Association, Executive Member of the Chinese Bio-engineering Association, Member of the Review Committee for the Chinese Medical Science and Technology Award and the Award for Chinese Medical Youth Talents, Member of the Editorial Committee for the Journal of the Chinese Bio-chemistry and Molecular Biology, Member of the Editorial Committee for the American Journal of Chinese Medical Developments, Permanent Member of the Editorial Committee for Medical Molecular Biology. She has got published a total of 298 academic papers in journals home and abroad, with 49 included by SCI.
l This lab cultivates and brings in young and middle-aged disciplinary forerunners and innovation-minded talents, strengthens its innovation team and optimizes the faculty make-up, achieving remarkable results in its team building. This Lab, with 26 tenure research members, among whom 2 were included in the provincial and municipal programs for talent priority development (Associate Prof. Wei Min and Associate Prof. Shi Rong). Among the staff members, Prof. Avran Hershko, the only winner of the Nobel Prize for life science in 2011, has been selected as one of the first batch of the leading scholars in Guangdong province and a foreign academician of the Chinese Academy of Sciences, granted the candidacy for the provincial-level One-thousand Talent, and won the Award for the Chinese Government Friendship.
Initiatives and Programs
1. Research into the Application of Genetic Chip Technology
This research, headed by Prof. Ma Wenli, has made headway as follows:
(1) Development of the chip for TCM chemical compounds targeted screening;
(2) Four-blood-pathogene (HIV、HBV、HCV、Syphilis ) integrated detection biochip
(3) Application of genetic chip technology in rapid detection of common viruses in entry and exit quarantine;
(4) Application of genetic chip technology in detecting virus EV71;
(5) Application of genetic chip technology in detecting GM food; and
(6) application of genetic chip technology in other fields.
2. Bio-informatics analysis of high-throughput bio-data
This research, headed by Prof. Zheng Wenling, focuses on the meta-analysis of genetic chip data, forging of the platform for gene-disease-medicine analysis, and the meta-analysis of SNP data.
3. Research on the Acting Molecular Mechanism of Tumor Genes and Tumor –suppressant Genes
This research, conducted by Prof. Shi Rong and Associate Prof. Wei Min, explores the molecular mechanism of the genes closely related with the pathogenesis and progression of tumors in liver cancer, breast cancer and acute leukemia.
Academic Exchanges
This Lab has been responsible for a good few academic conferences, including 08’China Regenerative Medicine and Stem Cells Conference (in Foshan, Guangdong), the 2nd China Genetic-Tech-Related Conference, China Vaccine Congress, and 09’ the 3rd China Genetic-Tech-Related Conference.
This Lab has dispatched three members to conduct academic exchanges in the U.S.A.
In cooperation with Beijing Husbandry and Vet Research Institute, Chinese Academy of Agricultural Sciences, this Lab has succeeded in breeding the Wuzhishan Miniature pig. And it has developed Brucella Detecting Kit jointly with Prof. Wang Ailin, Beihua University.
This lab makes cooperation with a good few universities and research bodies in China by making use of its human whole genome oligonucleotide expression profile chip platform, providing them with technical support and services. Meanwhile, the influenza virus oligonucleotide detecting chip, encephalitis and yellow fever viruses detecting chip and HIV detecting chip have found applications in China Entry-Exit Inspection and Quarantine Bureau.
Governmentally Funded Research Programs
This Lab has obtained a total of ￥15.076 million for its 50 state, provincial and municipal research programs. Besides, it has bagged ￥1.5 million, 0.3 million and 0.1 million for Guangdong Provincial Model Experimental Teaching Center for Biochemistry and Molecular Chemistry, State Teaching Team for Biochemistry, and Bilingual Teaching, respectively.
|
|
Title of Research Program
|
Funded by
|
Duration
|
Headed by
|
Fund (￥ thousand)
|
|
1
|
The Application of Biochips/RT-PCR in EV71 Detecting
|
Guangdong Provincial Department of Education
|
2008-2012
|
Ma Wenli
|
118
|
|
2
|
200910265 Standards for High-flux Detection of GM Content Based on Biochip/PCR/LAMP Technology (200910265)
|
General Administration of Quality Supervision, Inspection and Quarantine of PRC
|
2009-2011
|
Xiao Weiwei
|
78
|
|
3
|
（8451051501000265）TCM Chip Screening Based Targeted Activation of Anti-tumor Activity Component of P53 Protein (8451051501000265 )
|
Guangdong Provincial Natural Science Foundation Committee
|
2008-2010
|
Wu Qinghua
|
3
|
|
4
|
Preparation of Oligonucleotides Microarray for Screening Common HPVs
|
Guangdong Provincial Ministry of Science and Technology
|
2008-2010
|
Wei Min
|
1
|
|
5
|
Development of Genetic Detection Kit for Targeted Drug for Non-small Lung Cancer (2011B031800163)
|
Guangdong Provincial Ministry of Science and Technology
|
2011-2013
|
Zhang Bao
|
4
|
|
6
|
Development of Integrated Biochip Detection Kit for Four-blood-pathogene
|
Guangdong Provincial Ministry of Science and Technology
|
2007-2010
|
Li Ling
|
15
|
|
7
|
Development of Chip Detection Kit for Genetically Modified Food (2008B08701027)
|
Guangdong Provincial Ministry of Science and Technology
|
2009-2010
|
Xiao Weiwei
|
8
|
|
8
|
Berberine’s Inhibition of Histone Deacelylase and its Antitumor Activity (81073099)
|
State Natural Science Foundation Committee
|
2011-2013
|
Liang Shuang
|
33
|
|
9
|
Research on Tissue-specific Membrane Protein and Secretive Protein
|
Guangdong Provincial Department of Education
|
2009-2011
|
Liang Shuang
|
30
|
|
10
|
Building of Servicing Platform for Analysis of High-throughput Bio-medical Data (2010A040302003)
|
Guangdong Provincial Department of Education
|
2010-2012
|
Zhang Bao
|
15
|
|
11
|
Mammal Cell Surface Displaying Technique Based Screening of Anti- TNF-a Human Full-length Monoclonal Antibody
|
State Natural Science Foundation Committee
|
2012-2014
|
Zhou Ye
|
23
|
|
12
|
Mammal Cell Surface Displaying Technique Based Screening of Anti- TNF-a Monoclonal Antibody
|
Guangdong Provincial Natural Science Foundation Committee
|
2011-2013
|
Zhou Ye
|
3
|
|
13
|
Bio-informatic Research on Pathogenesis of Epilepsy and Role of Sakosaponin a（WSTJJ20081124130921198110052036）
|
Guangdong Provincial Health Department
|
2009-2011
|
Li Changzheng
|
1
|
|
14
|
The Molecular Mechanism of Asthenozoospermia by Bioinformatic Technique
|
Guangdong Provincial Health Department
|
2010-2012
|
Feng Chunqiong
|
0
|
|
15
|
Mammal Cell Surface Displaying Technique Based Screening of Anti- TNF-a Human Full-length Monoclonal Antibody
|
Guangdong Provincial Health Department
|
2011-2013
|
Li Changzheng
|
1
|
|
16
|
Molecular Action Pathway of Pin1 in Pathogenesis of Hepatocarcinoma（20094433110009）
|
The Chinese Ministry of Education
|
2009-2011
|
Ma Wenli
|
6
|
|
17
|
The Action Mechanism of FBXO31 in Hepatocarcinoma
|
Guangdong Provincial Organization Department
|
2011-2014
|
Avran Hershko
|
500
|
|
18
|
The Roles of FBXO31 on the Hepatocellular Carcinoma
|
Organization Department, CPC
|
2011-2014
|
Avran Hershko
|
50
|
|
19
|
Expression Regulation of CHD5 Tumour Suppressor Gene in Leukemia (81000226 )
|
State Natural Science Foundation Committee
|
2011-2013
|
Zhao Rui
|
20
|
|
20
|
Role and Mechanism of Ornithine Decarboxylase Antizyme in Erythroid Differentiation of K562 Cells （30901757）
|
State Natural Science Foundation Committee
|
2010-2012
|
Jiang Li
|
20
|
|
21
|
A Functional Study onAQP1 in Induced Differentiation of Erythroleukemia Cells. (30901721)
|
State Natural Science Foundation Committee
|
2010-2012
|
Wei Min
|
20
|
|
22
|
Inhibition of Breast Cancer Cell Apoptosis by Rheb Interacting withBcl-rambo (30900555)
|
State Natural Science Foundation Committee
|
2010-2012
|
Liu Anling
|
20
|
|
23
|
Regulation of Chromosome by Tumor-suppressant Gene CHD5
|
State Natural Science Foundation Committee
|
2012-2014
|
Yan Qitao
|
20
|
|
24
|
The Role and Molecular Mechanism of PinX1 Induced Mitotic Abnormity and Telomere Instability in Tumorigenesis (81101536)
|
State Natural Science Foundation Committee
|
2012-2014
|
Shi Rong
|
22
|
|
25
|
20104433120001/ The Role of PinX1 related DNA Damage in Carcinogenesis of Breast Cancer
|
The Chinese Ministry of Education
|
2011-2012
|
Shi Rong
|
3.6
|
|
26
|
The Mechanism of Telomerase Activation and its Role in the Formation of iPS Cells (Serial No. 40)
|
The Chinese Ministry of Education
|
2011-2012
|
Shi Rong
|
3
|
|
27
|
Cloning and Function of Specific miRNA in CML
|
The Chinese Ministry of Education
|
2008-2010
|
Song Yanbing
|
10
|
|
28
|
Methods for High Efficient iPS Induction and Mechanism of Telomerase Activation and Regulation (LYM09045)
|
Guangdong Provincial Department of Education
|
2009-2011
|
Shi Rong
|
3
|
|
29
|
2009B060700112/ The Establishment of a High =Efficienct Induction Platform and Role of Telomerase Activation in iPS Cells Formation
|
Guangdong Provincial Department of Science and Technology
|
2009-2011
|
Shi Rong
|
3
|
|
30
|
Experimental Research on FKBP38’s Inhibition of Breast Cancer （WSTJJ20081201362401197509251528）
|
Guangdong Provincial Health Department
|
2009-2011
|
Liu Anling
|
1
|
|
31
|
Regulation of Chromosome by Tumor-suppressant Gene CHD5 (S2011040005521)
|
Guangdong Provincial Natural Science Foundation Committee
|
2011-2013
|
Yan Qitao
|
3
|
|
32
|
Molecular Mechanism of Tumor Cells Proliferation by Artemisinin and its Derivatives Based on the Signalling Pathway of Fe2+ (S2011040003048)
|
|
2011-2013
|
Ding Dapeng
|
3
|
|
33
|
Role of MicroRNAs in Regulating Tumor Cell Cycle and the Mechanism (S2011040003050)
|
Guangdong Provincial Natural Science Foundation Committee
|
2011-2013
|
Zhou Jueyu
|
3
|
|
34
|
Study on ppGalNacT-2 Participation in Gathogenesis of Gastric Cancer (S2011040003098)
|
Guangdong Provincial Natural Science Foundation Committee
|
2011-2013
|
Gao Yuan
|
3
|
|
35
|
Role and Mechanism of FUS1’s Inhibition of Esophageal Carcinoma Cells (WSTJJ20081126142401198003202116)
|
Guangdong Provincial Health Department
|
2009-2011
|
Meng Wei
|
0
|
|
36
|
Study on Transcripting Mechanism of CHD5 Gene (A2011360)
|
Guangdong Provincial Health Department
|
2011-2013
|
Zhao Rui
|
1
|
|
37
|
Role of PinX1 in Carcinogenesis of Breast Cancer and its Epigenetic Mechanisms (2011055)
|
Guangzhou Municipal Bureau of Science and Technology
|
2012-2014
|
Shi Rong
|
60
|
|
38
|
Application of In Vitro Induced Differentiation of Human Umbilical Cord Interstitial Stem Cells into Islet-like and Neuron-like Cells
|
Business Cooperation
|
2010-2013
|
Song Yanbing
|
20
|
|
39
|
Regulation of CHD5 in Tumor Suppressant Network in Leukemia
|
The Chinese Ministry of Education
|
2010-2012
|
Zheng Wenling
|
6
|
Papers Published
This lab has got a total of 200-odd research papers published, with 40-odd in journals that have a highly rated impact factor such as Nat Cell Biol., J Clin Invest, JBC, Plose one, International Journal of Cancer.
1. Ding D, Zhang Y, Yu H, Guo Y, Jiang L, He X, Ma W, Zheng W. Genetic variation of XPA gene and risk of cancer: A systematic review and pooled analysis. Int J Cancer. 2011. doi: 10.1002/ijc.26391.
2. Ding DP, Zhang Y, Ma WL, He XF, Wang W, Yu HL, Guo YB, Zheng WL.Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls. J Cancer Res Clin Oncol. 2011;137(10):1463-8.
3. Ding DP, Ma WL, He XF, Zhang Y. XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies. Mol Biol Rep. 2012;39(3):2533-40.
4. Ding DP, Zhang Y, He XF. Lack of association between hOGG1 Ser326Cys polymorphism and breast cancer susceptibility in European population. Breast Cancer Res Treat. 2011;129(3):1023-6.
5. Zhang Y, Ding D, Wang X, Zhu Z, Huang M, He X. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies. Int J Colorectal Dis. 2011;26(10):1257-64.
6. Ding DP, He XF, Zhang Y. Lack of association between XPG Asp1104His and XPF Arg415Gln polymorphism and breast cancer risk: a meta-analysis of case-control studies. Breast Cancer Res Treat. 2011;129(1):203-9
7. Weiwei Liu, Wenling Zheng, Jun Xie, Bao Zhang, Xianjiu Chen, Wenli Ma. Identification of genes related to carcinogenesis of oral leukoplakia by oligo cancer microarray[J]. Oncol Rep. 2011, 26(1):265-274.
8. Huang HL, Zheng WL, Zhao R, Zhang B, Ma WL. FBXO31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma. Oncol Rep. 2010 Sep;24(3):715-20
9. Zhou Y, Chen ZR, Li CZ, He W, Liu S, Jiang S, Ma WL, Tan W, Zhou C A novel strategy for rapid construction of libraries of full-length antibodies highly expressed on mammalian cell surfaces. Acta Biochimica et Biophysica Sinica. 2010 Aug;42(8):575-84
10. Yan Qitao, Zhao Rui, Zheng Wenling, Yin Changxin, Zhang Bao, Ma Wenli. Generation of an external guide sequence library for a reverse genetic screen in Caenorhabditis elegans. BMC Biotechnol. 2009 May 20;9:47.
11. Zhou Jueyu,Ma Wenli, Liang Shuang, Zeng Ye, Shi Rong, Yu Hai-lang, Xiao Wei-wei, Zheng Wen-ling. Analysis of microRNA expression profiles during the cell cycle in synchronized HeLa cells. BMB reports. 2009, 42(9): 593-598
12. Wei Min, Ma Wenli, Sun Zhaohui,LI Ling, Zhang Bao, Zheng Wenling. Microarray analysis identifies differentially expressed genes induced by human papillomavirus type 18 E6 silencing RNA. Int J Gynecol Cancer. 2009;19(4):547-63.
13. ZUO Changqing, Liang Shuang, Li Hua, Zheng Wenling, Ma Wenli. Enriching protein-protein and functional interaction networks in human embryonic stem cells. Int J Mol Med. 2009, 23(6): 811-819
14. Cao Donglin, Hu Liangshan, Wang Yang, Wang Ling, Zheng Wenling, Ma Wenli. Suppression of graft-versus-host disease after adoptive infusion of alloreactive NK cells induced by silencing Ly49C gene in mice. Transpl Immunol. 2009;20(4):243-8.
15. Wu Q, Ma W, Zhu L, Guo Q, Zhang B, Kulageri SM, Zheng W. Oligo-microarray based on oligonucleotide immobilization on glass surface modified with activated acrylic acid-co-acrylamide copolymer. J Biomed Mater Res B Appl Biomater. 2008;87(1):67-72
16. Chen X, Liang S, Zheng W, Liao Z, Shang T, Ma W. Meta-analysis of nasopharyngeal carcinoma microarray data explores mechanism of EBV-regulated neoplastic transformation. BMC Genomics. 2008;9:322.
17. Liu Anling. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer letters，2010，297(1):117-25
18. Soohoo C, Shi R, Lee TH, Huang PY, Lu KP, Zhou XZ. Telomerase inhibitor PinX1 provides a link between TRF1 and telomerase to prevent telomere elongation. J Biol Chem. 2011, 286(5):3894-906.
19. Zhou XZ, Huang P, Shi R, Lee TH, Lu G, Zhang Z, Bronson R, Lu KP.The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice.J Clin Invest. 2011, 121(4):1266-82.
Lee TH, Tun-Kyi A, Shi R, Lim J, Soohoo C, Finn G, Balastik M, Pastorino L, Wulf G, Zhou XZ, Lu KP. Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nat Cell Biol. 2009,11(1): 97-105
Patents Granted
1. Title of Patent: A Universal Primer Labelling (Patent Number: ZL200510033396.0)
Time of Patent: Jan. 2008
Assignee / Owner of Patent: Ma Wenli, Zheng Wenling, Xu Qiulin, Shi Rong, Li Ling
2. Title of Patent: An Integrated Capillary Electrophoresis Chip Scanning and Analyzing System and the Method (Patent Number: ZL200610025229.6)
Time of Patent: Nov. 2008
Assignee / Owner of Patent: Ma Wenli, Zheng Wenling, Liu Lili
3. Title of Patent: A Method of Treating Biochip Surface (Patent Number: ZL 200410027316.6 )
Time of Patent: Aug. 2006
Assignee / Owner of Patent: Ma Wenli, Zheng Wenling, Wu Qinghua
4. Title of Patent: A TCM Biochip Substrate and its Preparation and Function (Patent Number: ZL 201010151913.5 )
Time of Patent: Jan. 2013
Assignee / Owner of Patent:Wu Qinghua, Zhang Bao, Ma Wenli, Shen Qun, Zheng Wenling
5. Title of Patent: A Targeted Externally-directed Sequence for c-myc Carcinoma Gene (Patent Number: ZL200910162322.5 )
Time of Patent: Jan. 2011
Assignee / Owner of Patent: Zheng Wenling, Yan Qitao, Liu Yuanyuan, Ma Wenli
6. Title of Patent: A Mosquito-dispelling Sticker. (Patent Number: ZL200820202357.8 )
Time of Patent: Aug. 2000
Assignee / Owner of Patent: Zheng Wenling, Ma Wenli, Liu Yuanyuan
7. Title of Patent: A Quick Method of Pathogenic Microorganisms by a Diagnostic Genetic Chip. (Patent Number: ZL200420044241.8 )
Time of Patent: May. 2005
Assignee / Owner of Patent: Ma Wenli, Zheng Wenling, Yuan Yuefeng
8. Title of Patent: A Quick Method of Pathogenic Microorganisms by a Diagnostic Genetic Chip. (Patent Number: ZL03113853.5 )
Time of Patent: Dec. 2006
Assignee / Owner of Patent: Ma Wenli, Zheng Wenling, Shi Rong
9. Title of Patent: A Restrictive Fluorescence Labelling. (Patent Number: ZL 02134540.6)
Time of Patent: Aug. 2007
Assignee / Owner of Patent: Ma Wenli, Zheng Wenling, Li Ling
10. Title of Patent: Building of a Subtractive Hybrid Device. (Patent Number: ZL 200310112066.1)
Time of Patent: Dec. 2005
Assignee / Owner of Patent: Ma Wenli, Zheng Wenling, Song Yanbin
11. Title of Patent: A Subtractive Hybrid Device. (Patent Number: ZL 200320117835.2) Time of Patent: Nov. 2004
Assignee / Owner of Patent: Ma Wenli, Zheng Wenling, Song Yanbin
